Targeting ROS in cancer: rationale and strategies
Issued Date
2024-01-01
Resource Type
ISSN
14741776
eISSN
14741784
Scopus ID
2-s2.0-85197755335
Journal Title
Nature Reviews Drug Discovery
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Reviews Drug Discovery (2024)
Suggested Citation
Glorieux C., Liu S., Trachootham D., Huang P. Targeting ROS in cancer: rationale and strategies. Nature Reviews Drug Discovery (2024). doi:10.1038/s41573-024-00979-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99662
Title
Targeting ROS in cancer: rationale and strategies
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Reactive oxygen species (ROS) in biological systems are transient but essential molecules that are generated and eliminated by a complex set of delicately balanced molecular machineries. Disruption of redox homeostasis has been associated with various human diseases, especially cancer, in which increased ROS levels are thought to have a major role in tumour development and progression. As such, modulation of cellular redox status by targeting ROS and their regulatory machineries is considered a promising therapeutic strategy for cancer treatment. Recently, there has been major progress in this field, including the discovery of novel redox signalling pathways that affect the metabolism of tumour cells as well as immune cells in the tumour microenvironment, and the intriguing ROS regulation of biomolecular phase separation. Progress has also been made in exploring redox regulation in cancer stem cells, the role of ROS in determining cell fate and new anticancer agents that target ROS. This Review discusses these research developments and their implications for cancer therapy and drug discovery, as well as emerging concepts, paradoxes and future perspectives.